Open AccessPseudoprogression in patients with glioblastoma: clinical relevance despite low incidence
Author(s) -
Alexander Radbruch,
Joachim Fladt,
Philipp Kickingereder,
Benedikt Wiestler,
Martha Nowosielski,
P. Bäumer,
HP Schlemmer,
Antje Wick,
Sabine Heiland,
Wolfgang Wick,
M. Bendszus
Publication year - 2014
Publication title -
neuro-oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.005
H-Index - 125
eISSN - 1523-5866
pISSN - 1522-8517
DOI - 10.1093/neuonc/nou129
Subject(s) - glioblastoma , incidence (geometry) , medicine , clinical significance , relevance (law) , oncology , cancer research , mathematics , political science , law , geometry
According to the Response Assessment in Neuro-Oncology criteria, new enhancement within the radiation field on contrast enhanced T1-weighted images within 12 weeks after completion of radiotherapy should not qualify for progressive disease, since up to 50% of these cases may be pseudoprogression (PsP). To validate this concept, we assessed incidence and overall survival (OS) of patients with suspected and confirmed PsP dependent on different time intervals and definitions of PsP.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom